Obesity Treatment
Are GLP-1 drugs the end of bariatric surgery and lifestyle interventions?
A (Bariatric Surgeon): No. Surgery still achieves greater and more durable weight loss. Roux-en-Y gastric bypass (RYGB) achieves 30-35% total weight loss at 5 years, compared to 15-20% for GLP-1s. For patients with BMI > 40 or with severe comorbidities, surgery is superior. Also, surgery is one-time cost (~$25,000) vs. lifetime drug cost (~$12,000/year).
B (Endocrinologist - Obesity Medicine): But patients don't want scalpels. Oral formulations of GLP-1s (semaglutide pill, danuglipron) are coming. Adherence will be higher than injections. Also, combination therapy—low-dose GLP-1 plus lifestyle—may be the optimal approach for many, avoiding both surgery and high-dose drug side effects.
C (Health Ethicist): We are medicalizing a societal problem. These drugs treat the symptom (excess weight) but not the cause (food environment, food deserts, ultra-processed foods, stress, sleep deprivation). Who pays for a lifetime of $1,200/month injections for 40% of American adults? That's $2 trillion over 10 years. We need public health interventions, not just pharmacology.
D (Patient - BMI 38): I lost 50 lbs on Wegovy. My joint pain is gone, my sleep apnea resolved, I can play with my kids. Call it "medicalizing" if you want, but it works. Stop shaming obese people for needing medication. We don't tell cancer patients to just try diet and exercise.